Recurrent cancer

Last updated

Recurrent cancer is any form of cancer that has returned or recurred when a fraction of primary tumor cells evade the effects of treatment and survive in small spaces that are undetectable by diagnostic tests. The initial tumor may become the site of cancer's return or it may spread to another part of the body. [1] These surviving cells accumulate various genetic changes over time, eventually producing a new tumor cell. It can take up to weeks, months, or even years for cancer to return. Following surgery and/or chemotherapy or radiotherapy, certain tumor cells may persist and develop resistance to treatment and eventually develop into new tumors. The rate of cancer recurrence is determined by many factors, including age, sex, cancer type, treatment duration, stage of advancement, grade of original tumor, and cancer-specific risk factors. [2] [3] [4] If recurrent cancer has already moved to other body parts or has developed chemo-resistance then it may be more aggressive than original cancer. In general, the severity of cancer increases with a shorter duration of time between initial treatment and its return. [3]

Contents

Cancers with the highest recurrence rates include Glioblastoma with a recurrence rate of almost 100%, [5]   Epithelial ovarian cancer with a recurrence rate of 85%, [6] and Bladder cancer with a recurrence rate of 30-54% [7]

Types

There are three types of recurrent cancers:

Causes

Cancer stem cells

Cancer stem cells (CSC) are a small population of the entire tumor cell mass, that are responsible for early formation, progression, and recurrence of cancer. It also contributes to drug resistance. [13] [14] CSCs are thought to originate from normal stem cells, progenitor cells or differentiated cells as a result of cumulative genetic mutation and subsequent genomic instability. [15] They are found in the tumor microenvironment's specialized niches. CSCs have so far been found in a variety of tumors, including those of the brain, breast, ovary, head and neck, etc. [16] [17] [18] [19] [20]

CSCs have the ability of self-proliferation just like regular stem cells. A single CSC can divide asymmetrically into one CSC and one differentiated tumor cell. The tumor is majority made up of the latter cells. [21]

In some cancers CSCs are quiescent for long period of time, making them ineffective to the treatment. Therefore, even decades after the primary cancer has been fully treated, the reactivation of the inactive CSCs may lead to tumor recurrence. [22] [23]

Neosis

Hypoxia, chemotherapeutic agents, and radiation can generate Polyploid Giant Cancer Cells (PGCC). Some PGCCs have the ability to undergo neosis, which is characterized by nuclear budding karyokinesis, asymmetric intracellular cytokinesis and the generation of Raju cells, which are tiny mononuclear cells having stem cell like characteristics. These cells play a role in cancer recurrence and therapy resistance. [24]

Phoenix rising

Phoenix rising is a process by which dead cells send signals that promote growth and division, generating new cells. [25] After a tissue injury, stem cells present in and around the injured tissue play a crucial role in replenishing the damaged ones. It is theorized that molecules released from wounded cells trigger stem cells' migration to that site, followed by differentiation and proliferation. [26] Through the process of apoptosis, the dying tumor cells provide growth signals and repair radiation-damaged tumors. PGE2 is released by apoptotic cells in a caspase-dependent manner, which aids cancer stem cells and cancer progenitor cells in expanding and multiplying. [27]

Cell stress and dormancy

Cancer recurrence (relapse) is ascribed to malignant cells that evade therapy: small numbers of cancer cells may remain undetected, and dormant, pausing their proliferation for long time. This can occur also by mechanisms different from cell cycle quiescence. [28] [29] In fact, the effects of therapy that kills most cancer cells, may cause a few of them to pause proliferation instead of dying. [30] While the precise mechanism of growth arrest is not entirely clear and may not be uniform across cancer cases, malignant cells that survive chemotherapy make several metabolic adaptations and possess altered configuration of key positions of their chromatin, the material that packages their DNA. This has as result that certain conditions can trigger expression of genes that reignite cancer cell growth, causing proliferation, and additionally these conditions may trigger aberrant expression of genes that cause changes in the host tissue, which also permit cancer growth. [31]

Diagnosis

Early diagnosis of recurrence is important and can improve the prognosis and survival of patients with cancer. [32] Depending on the primary cancer type, several laboratory and imaging tests, as well as numerous invasive procedures, are used for the diagnosis of recurring cancers. [33] [34] Malignant tumors develop and secrete biologic chemicals known as tumor markers that are detectable in the bloodstream. These markers might ideally be used to screen for cancer, diagnose it, and track how effectively it responds to treatment. [35]

Treatment

The inherent limits of current cancer therapy approaches usually result in treatment failure. Chemotherapy and radiation therapy resistance is a common factor in the failure of treatment for many cancers. [36] Additionally, because most treatments cannot completely eradicate CSCs, many methods that are not adequately selective against CSCs might be harmful to healthy tissues, and patients frequently run the risk of recurrence and metastasis. [37]

Recent years have seen the development of numerous treatments with the goal of eliminating CSC. Targeting CSC surface markers, the ABC cascade, the microenvironment, or signal cascades could all help kill CSCs. There are numerous drugs targeting these markers or pathways, which are being tested in clinical trials. The treatment varies from cancer to cancer and patient to patient. [38] [39] [40] [41]

References

  1. ↑ "https://www.cancer.gov/publications/dictionaries/cancer-terms/def/recurrent-cancer". www.cancer.gov. 2011-02-02. Retrieved 2022-10-07.{{cite web}}: External link in |title= (help)
  2. ↑ Baker, Frank; Denniston, Maxine; Smith, Tenbroeck; West, Michele M. (2005). "Adult cancer survivors: How are they faring?". Cancer. 104 (S11): 2565–2576. doi:10.1002/cncr.21488. ISSN   0008-543X. PMID   16258929. S2CID   37025588.
  3. 1 2 "Cancer Recurrence - Why Does Cancer Come Back". Cancer Treatment Centers of America. 2021-07-15. Retrieved 2022-10-07.
  4. ↑ Doroudian, Sepehr; Osterman, Erik; Glimelius, Bengt (2024-06-09). "Risk Factors for Recurrence After Surgery for Rectal Cancer in a Modern, Nationwide Population-Based Cohort". Annals of Surgical Oncology. 31 (9): 5570–5584. doi: 10.1245/s10434-024-15552-x . ISSN   1068-9265. PMC   11300512 . PMID   38853216.
  5. ↑ van Linde, Myra E.; Brahm, Cyrillo G.; de Witt Hamer, Philip C.; Reijneveld, Jaap C.; Bruynzeel, Anna M. E.; Vandertop, W. Peter; van de Ven, Peter M.; Wagemakers, Michiel; van der Weide, Hiske L.; Enting, Roelien H.; Walenkamp, Annemiek M. E.; Verheul, Henk M. W. (2017-10-01). "Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis". Journal of Neuro-Oncology. 135 (1): 183–192. doi:10.1007/s11060-017-2564-z. ISSN   1573-7373. PMC   5658463 . PMID   28730289.
  6. ↑ Corrado, Giacomo; Salutari, Vanda; Palluzzi, Eleonora; Distefano, Maria Grazia; Scambia, Giovanni; Ferrandina, Gabriella (2017-12-02). "Optimizing treatment in recurrent epithelial ovarian cancer". Expert Review of Anticancer Therapy. 17 (12): 1147–1158. doi:10.1080/14737140.2017.1398088. ISSN   1473-7140. PMID   29086618. S2CID   4715924.
  7. ↑ Mari, Andrea; Campi, Riccardo; Tellini, Riccardo; Gandaglia, Giorgio; Albisinni, Simone; Abufaraj, Mohammad; Hatzichristodoulou, Georgios; Montorsi, Francesco; van Velthoven, Roland; Carini, Marco; Minervini, Andrea; Shariat, Shahrokh F. (2018-02-01). "Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature". World Journal of Urology. 36 (2): 157–170. doi:10.1007/s00345-017-2115-4. ISSN   1433-8726. PMC   5799348 . PMID   29147759.
  8. ↑ Mahvi, David A.; Liu, Rong; Grinstaff, Mark W.; Colson, Yolonda L.; Raut, Chandrajit P. (November 2018). "Local Cancer Recurrence: The Realities, Challenges, and Opportunities for New Therapies: XXXX". CA: A Cancer Journal for Clinicians. 68 (6): 488–505. doi:10.3322/caac.21498. PMC   6239861 . PMID   30328620.
  9. ↑ Abulafi, A M; Williams, N S (January 1994). "Local recurrence of colorectal cancer: The problem, mechanisms, management and adjuvant therapy". British Journal of Surgery. 81 (1): 7–19. doi:10.1002/bjs.1800810106. ISSN   0007-1323. PMID   8313126. S2CID   23957292.
  10. ↑ Ritoe, Savitri C.; Verbeek, André L. M.; Krabbe, Paul F. M.; Kaanders, Johannes H. A. M.; van den Hoogen, Frank J. A.; Marres, Henri A. M. (2007). "Screening for local and regional cancer recurrence in patients curatively treated for laryngeal cancer: Definition of a high-risk group and estimation of the lead time". Head & Neck. 29 (5): 431–438. doi:10.1002/hed.20534. ISSN   1043-3074. PMID   17120311. S2CID   32773921.
  11. ↑ Lehnert, T.; Rudek, B.; Buhl, K.; Golling, M. (2002-06-01). "Surgical therapy for loco-regional recurrence and distant metastasis of gastric cancer" . European Journal of Surgical Oncology. 28 (4): 455–461. doi:10.1053/ejso.2002.1260. ISSN   0748-7983. PMID   12099659.
  12. ↑ Varlotto, John M.; Recht, Abram; Flickinger, John C.; Medford-Davis, Laura N.; Dyer, Ann M.; DeCamp, Malcolm M. (2009-03-01). "Factors associated with local and distant recurrence and survival in patients with resected nonsmall cell lung cancer". Cancer. 115 (5): 1059–1069. doi: 10.1002/cncr.24133 . ISSN   0008-543X. PMID   19152440. S2CID   205654128.
  13. ↑ Pang, Lisa Y.; Argyle, David (July 2010). "Cancer stem cells and telomerase as potential biomarkers in veterinary oncology". The Veterinary Journal. 185 (1): 15–22. doi:10.1016/j.tvjl.2010.04.008. ISSN   1090-0233. PMID   20580998.
  14. ↑ Visvader, Jane E.; Lindeman, Geoffrey J. (June 2012). "Cancer Stem Cells: Current Status and Evolving Complexities". Cell Stem Cell. 10 (6): 717–728. doi: 10.1016/j.stem.2012.05.007 . ISSN   1934-5909. PMID   22704512.
  15. ↑ Peitzsch, Claudia; Tyutyunnykova, Anna; Pantel, Klaus; Dubrovska, Anna (June 2017). "Cancer stem cells: The root of tumor recurrence and metastases". Seminars in Cancer Biology. 44: 10–24. doi:10.1016/j.semcancer.2017.02.011. ISSN   1044-579X. PMID   28257956.
  16. ↑ Al-Hajj, Muhammad; Wicha, Max S.; Benito-Hernandez, Adalberto; Morrison, Sean J.; Clarke, Michael F. (April 2003). "Prospective identification of tumorigenic breast cancer cells". Proceedings of the National Academy of Sciences. 100 (7): 3983–3988. Bibcode:2003PNAS..100.3983A. doi: 10.1073/pnas.0530291100 . ISSN   0027-8424. PMC   153034 . PMID   12629218.
  17. ↑ Pang, Lisa Y.; Cervantes-Arias, Alejandro; Else, Rod W.; Argyle, David J. (2011-03-30). "Canine Mammary Cancer Stem Cells are Radio- and Chemo- Resistant and Exhibit an Epithelial-Mesenchymal Transition Phenotype". Cancers. 3 (2): 1744–1762. doi: 10.3390/cancers3021744 . ISSN   2072-6694. PMC   3757388 . PMID   24212780.
  18. ↑ Wang, Xin; Venugopal, Chitra; Singh, Sheila K. (2011), "Cancer Stem Cells in Brain Cancer", Cancer Stem Cells in Solid Tumors, Totowa, NJ: Humana Press, pp. 37–56, doi:10.1007/978-1-61779-246-5_3, ISBN   978-1-61779-245-8
  19. ↑ Major, Aidan G.; Pitty, Luke P.; Farah, Camile S. (2013-03-03). "Cancer Stem Cell Markers in Head and Neck Squamous Cell Carcinoma". Stem Cells International. 2013 e319489. doi: 10.1155/2013/319489 . ISSN   1687-966X. PMC   3603684 . PMID   23533441.
  20. ↑ Rizzo, S.; Attard, G.; Hudson, D. L. (December 2005). "Prostate epithelial stem cells". Cell Proliferation. 38 (6): 363–374. doi:10.1111/j.1365-2184.2005.00356.x. ISSN   0960-7722. PMC   6496238 . PMID   16300650.
  21. ↑ Jordan, Craig T.; Guzman, Monica L.; Noble, Mark (2006-09-21). "Cancer Stem Cells". New England Journal of Medicine. 355 (12): 1253–1261. doi:10.1056/nejmra061808. ISSN   0028-4793. PMID   16990388.
  22. ↑ Allan, Alison L.; Vantyghem, Sharon A.; Tuck, Alan B.; Chambers, Ann F. (2007-04-12). "Tumor Dormancy and Cancer Stem Cells: Implications for the Biology and Treatment of Breast Cancer Metastasis". Breast Disease. 26 (1): 87–98. doi:10.3233/bd-2007-26108. ISSN   1558-1551. PMID   17473368.
  23. ↑ Ojha, Rani; Bhattacharyya, Shalmoli; Singh, Shrawan K. (December 2015). "Autophagy in Cancer Stem Cells: A Potential Link Between Chemoresistance, Recurrence, and Metastasis". BioResearch Open Access. 4 (1): 97–108. doi:10.1089/biores.2014.0035. ISSN   2164-7860. PMC   4497670 . PMID   26309786.
  24. ↑ Zhang, Zhengxiang; Feng, Xiao; Deng, Zheng; Cheng, Jin; Wang, Yiwei; Zhao, Minghui; Zhao, Yucui; He, Sijia; Huang, Qian (August 2021). "Irradiation-induced polyploid giant cancer cells are involved in tumor cell repopulation via neosis". Molecular Oncology. 15 (8): 2219–2234. doi:10.1002/1878-0261.12913. ISSN   1574-7891. PMC   8334289 . PMID   33523579.
  25. ↑ Pang, Lisa Y.; Hurst, Emma A.; Argyle, David J. (2016). "Cyclooxygenase-2: A Role in Cancer Stem Cell Survival and Repopulation of Cancer Cells during Therapy". Stem Cells International. 2016: 1–11. doi: 10.1155/2016/2048731 . ISSN   1687-966X. PMC   5108861 . PMID   27882058.
  26. ↑ Boland, K; Flanagan, L; Prehn, J HM (July 2013). "Paracrine control of tissue regeneration and cell proliferation by Caspase-3". Cell Death & Disease. 4 (7): e725. doi:10.1038/cddis.2013.250. ISSN   2041-4889. PMC   3730423 . PMID   23846227.
  27. ↑ Zimmerman, Mary A.; Huang, Qian; Li, Fang; Liu, Xinjiang; Li, Chuan-Yuan (October 2013). "Cell Death–Stimulated Cell Proliferation: A Tissue Regeneration Mechanism Usurped by Tumors During Radiotherapy". Seminars in Radiation Oncology. 23 (4): 288–295. doi:10.1016/j.semradonc.2013.05.003. ISSN   1053-4296. PMC   3891050 . PMID   24012343.
  28. ↑ Truskowski, K; et, al (Mar 2023). "Dormant cancer cells: programmed quiescence, senescence, or both?". Cancer Metastasis Rev. 42 (1): 37–47. doi:10.1007/s10555-022-10073-z. PMC   10014758 . PMID   36598661.
  29. ↑ Tamamouna, V; et, al (11 Nov 2022). "Regulation of Metastatic Tumor Dormancy and Emerging Opportunities for Therapeutic Intervention". Int J Mol Sci. 23 (22) 13931. doi: 10.3390/ijms232213931 . PMC   9698240 . PMID   36430404.
  30. ↑ Aleksandrova, KV; et, al (28 Feb 2024). "mTOR pathway occupies a central role in the emergence of latent cancer cells". Cell Death Dis. 15 (2): 176. doi:10.1038/s41419-024-06547-3. PMC   10902345 . PMID   38418814.
  31. ↑ Vlahopoulos, SA (2024). "Divergent Processing of Cell Stress Signals as the Basis of Cancer Progression: Licensing NFκB on Chromatin". International Journal of Molecular Sciences. 25 (16): 8621. doi: 10.3390/ijms25168621 . PMC   11354898 . PMID   39201306.
  32. ↑ Schneble, Erika J.; Graham, Lindsey J.; Shupe, Matthew P.; Flynt, Frederick L.; Banks, Kevin P.; Kirkpatrick, Aaron D.; Nissan, Aviram; Henry, Leonard; Stojadinovic, Alexander; Shumway, Nathan M.; Avital, Itzhak; Peoples, George E.; Setlik, Robert F. (2014). "Current Approaches and Challenges in Early Detection of Breast Cancer Recurrence". Journal of Cancer. 5 (4): 281–290. doi:10.7150/jca.8016. ISSN   1837-9664. PMC   3982041 . PMID   24790656.
  33. ↑ Israel, Ora; Kuten, Abraham (2007-01-01). "Early Detection of Cancer Recurrence: 18F-FDG PET/CT Can Make a Difference in Diagnosis and Patient Care". Journal of Nuclear Medicine. 48 (1 suppl): 28S –35S. ISSN   0161-5505. PMID   17204718.
  34. ↑ Panebianco, Valeria; Barchetti, Flavio; Musio, Daniela; De Felice, Francesca; Proietti, Camilla; Indino, Elena Lucia; Megna, Valentina; Schillaci, Orazio; Catalano, Carlo; Tombolini, Vincenzo (2014-03-13). "Advanced Imaging for the Early Diagnosis of Local Recurrence Prostate Cancer after Radical Prostatectomy". BioMed Research International. 2014 e827265. doi: 10.1155/2014/827265 . ISSN   2314-6133. PMC   3971570 . PMID   24757679.
  35. ↑ Sauter, Edward R. (2017-10-01). "Reliable Biomarkers to Identify New and Recurrent Cancer". European Journal of Breast Health. 13 (4): 162–167. doi:10.5152/ejbh.2017.3635. ISSN   2587-0831. PMC   5648271 . PMID   29082372.
  36. ↑ Zhao, Jihe (April 2016). "Cancer stem cells and chemoresistance: The smartest survives the raid". Pharmacology & Therapeutics. 160: 145–158. doi:10.1016/j.pharmthera.2016.02.008. ISSN   0163-7258. PMC   4808328 . PMID   26899500.
  37. ↑ Abdullah, Lissa Nurrul; Chow, Edward Kai-Hua (2013-01-17). "Mechanisms of chemoresistance in cancer stem cells". Clinical and Translational Medicine. 2 (1): 3. doi: 10.1186/2001-1326-2-3 . ISSN   2001-1326. PMC   3565873 . PMID   23369605.
  38. ↑ Chen, Ke; Huang, Ying-hui; Chen, Ji-long (2013-05-20). "Understanding and targeting cancer stem cells: therapeutic implications and challenges". Acta Pharmacologica Sinica. 34 (6): 732–740. doi:10.1038/aps.2013.27. ISSN   1671-4083. PMC   3674516 . PMID   23685952.
  39. ↑ Yang, Liqun; Shi, Pengfei; Zhao, Gaichao; Xu, Jie; Peng, Wen; Zhang, Jiayi; Zhang, Guanghui; Wang, Xiaowen; Dong, Zhen; Chen, Fei; Cui, Hongjuan (2020-02-07). "Targeting cancer stem cell pathways for cancer therapy". Signal Transduction and Targeted Therapy. 5 (1): 8. doi:10.1038/s41392-020-0110-5. ISSN   2059-3635. PMC   7005297 . PMID   32296030.
  40. ↑ Yoshida, Go J.; Saya, Hideyuki (2015-10-21). "Therapeutic strategies targeting cancer stem cells". Cancer Science. 107 (1): 5–11. doi:10.1111/cas.12817. ISSN   1347-9032. PMC   4724810 . PMID   26362755.
  41. ↑ Mambet, Cristina; Chivu-Economescu, Mihaela; Matei, Lilia; Necula, Laura Georgiana; Dragu, Denisa Laura; Bleotu, Coralia; Diaconu, Carmen Cristina (2018-06-26). "Murine models based on acute myeloid leukemia-initiating stem cells xenografting". World Journal of Stem Cells. 10 (6): 57–65. doi: 10.4252/wjsc.v10.i6.57 . ISSN   1948-0210. PMC   6033712 . PMID   29988882.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.